Xilio Therapeutics, Inc. (XLO)

NASDAQ: XLO · USD

$8.00

-0.01 (-0.1%)· Recorded snapshot

Market cap	52.6M
Revenue (ttm)	64.1M
Net income (ttm)	-21.8M
EPS (ttm)	-$3.32
Shares out	6.6M
Volume	13,090
Beta	-0.12

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 64.1M
Net income (ttm): -21.8M
EPS (ttm): -$3.32
Market cap: 52.6M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Держать

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-55

P25 n/aP50 n/aP75 n/a

ROIC-42.1

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All XLO indicators

Market & fundamental data

Available fields

196

Groups with data

Currency

USD

Showing 196 of 196 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001840233
Company name	Xilio Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	98422T209
Earnings date	2026-11-12
Earnings time	bmo
Employees	76
Employees change	12
Employees growth	18.75%
Enterprise value	$-77.1M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2016
Industry	Biotechnology
IPO date	2021-10-22
Is primary listing	Yes
Is SPAC	No
ISIN number	US98422T2096
Last 10-K release date	2026-03-23
Last earnings date	2026-08-12
Last refreshed	2026-10-28
Last stock split date	2026-03-16
Last stock split type	Reverse
Market cap	$52.6M
Market cap category	Micro-Cap
Next earnings date	2026-11-12
Options	No
Price	$8.00
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	XLO
U.S. state	Massachusetts
Website	https://xiliotx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-41.47%
FCF / EV yield	79.54%
FCF yield	-116.24%
Forward P/S	1.26x
P/B ratio	0.73x
P/S ratio	0.82x
Price / tangible book value	0.73x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-48.94%
EBITDA margin	-46.85%
Gross margin	83.16%
Operating margin	-48.94%
Pretax margin	-34.06%
Profit margin	-34.06%
Profit per employee	$-287,224
Revenue per employee	$843,316
ROA	-13.61%
ROA (5Y)	-39.45%
ROCE	-26.13%
ROE	-55.03%
ROE (5Y)	-119.72%
ROIC	-42.07%
SBC / revenue	12.27%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	13
EPS growth years	5
Gross profit growth	309.32%
Net income growth quarters	3
Net income growth years	3
Revenue growth	327.25%
Revenue growth (Q)	131.22%
Revenue growth (QoQ)	47.79%
Revenue growth quarters	5
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-670,000
Depreciation and amortization	$1.3M
EBIT	$-31.4M
EBITDA	$-30M
EPS	$-3.32
FCF per share	$-9.31
Financing cash flow	$75.8M
Free cash flow	$-61.3M
Free cash flow minus SBC	$-69.1M
Gross profit	$53.3M
Investing cash flow	$-670,000
Net cash flow	$14.5M
Net income	$-21.8M
Operating cash flow minus SBC	$-68.5M
Operating income	$-31.4M
Revenue	$64.1M
Stock-based compensation	$7.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-3.03
Book value per share	$10.98
Debt / equity	0.09
Long-term assets	$8.8M
Long-term liabilities	$47.8M
Net cash (debt)	$129.7M
Net cash / market cap	246.15%
Net cash growth	13.82%
Net debt / equity	-1.8
Piotroski F-Score	2
Property, plant and equipment	$7M
Shareholders' equity	$72.3M
Tangible book value	$72.3M
Tangible book value per share	$10.98
Total assets	$154.3M
Total cash	$136M
Total debt	$6.3M
Total liabilities	$82M
WACC	3.2%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.44
Current assets	$145.5M
Current liabilities	$34.2M
Current ratio	4.25
Net working capital	$-23.3M
Quick ratio	4.15
Working capital	$111.3M
Working capital turnover	0.71

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-77.75%
Dividend yield	0%
Shareholder yield	-77.75%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$8.69
1D price change	-0.12%
1M price change	-8.3%
1M total return	-8.3%
1W price change	-1.66%
1W total return	-1.66%
1Y price change	-28.7%
1Y return CAGR	-28.72%
1Y total return	-28.7%
20-day SMA	$8.62
200-day SMA	$8.51
3M price change	-8.8%
3M total return	-8.8%
3Y price change	-71.39%
3Y return CAGR	-34.1%
3Y total return	-71.39%
50-day SMA	$8.86
50-day SMA vs 200-day SMA	50over200
52-week high	$12.59
52-week high date	2025-10-30
52-week low	$6.47
52-week low date	2026-03-12
5Y price change	-96.32%
5Y return CAGR	-48.34%
5Y total return	-96.32%
6M price change	1.35%
6M total return	1.35%
All-time high	$391.30
All-time high date	2021-11-16
All-time low	$6.47
All-time low date	2026-03-12
Average true range (ATR)	$0.55
Average volume	15.3K
Beta (1Y)	0.14
Beta (2Y)	0.24
Beta (5Y)	-0.12
Change from 52-week high	-36.43%
Change from 52-week low	23.74%
Change from all-time high	-97.88%
Change from all-time low	28.23%
Change from open	0.63%
Day's gap	-0.75%
Dollar volume	$104,720
High price	$8.00
Low price	$7.95
Monthly RSI	31.46
Open price	$7.95
Position in 52-week range	100%
Previous close	$8.01
Price vs 150-day SMA	-4.58%
Price vs 20-day SMA	-3.82%
Price vs 200-day SMA	-2.56%
Price vs 50-day SMA	-6.48%
Relative volume	0.86
Return from IPO open	-96.19%
Return from IPO price	-49.94%
RSI	45.21
Sharpe ratio	-0.61
Sharpe ratio (3Y)	0.17
Sortino ratio	-0.77
Sortino ratio (3Y)	0.41
Volume	13.1K
Weekly RSI	44.75
YTD price change	-7.51%
YTD total return	-7.51%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	3.4M
Float percentage	51.71%
Shares change (QoQ)	13.79%
Shares change (YoY)	77.75%
Shares held by insiders	8.17%
Shares held by institutions	26.29%
Shares outstanding	6.6M
Short % of float	12.05%
Short % of shares	6.23%
Short ratio	39 days

Deeper analysis on XLO

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this XLO report

Is a complete XLO research report available?

No complete published report is available for Xilio Therapeutics, Inc. (XLO) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Xilio Therapeutics, Inc. (XLO)

Price

Financial snapshot

Fair-value bridge

Latest news · XLO

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All XLO indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on XLO

Frequently asked questions